glp-1/gip/glucagon triple agonist name Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care TrimRX | GLP-1 vs GIP:
Description
The TRIUMPH 4 study showed that patients with obesity and knee arthritis lost an average of almost 29% of their body weight - an average weight loss of 71 pounds
Colleagues and peers remember him being close to tears at meetings in Europe when no one showed interest in licensing his Gila peptide
10.1111/obr.12465 [DOI] [PubMed] 2.Leitner DR et al (2017) Obesity and type 2 diabetes: two diseases with a need for combined treatment strategiesEASO Can lead the way
Combining mono- and/or dual-agonists to achieve triple agonism may allow for personalisation of treatment, aiming to find the optimal balance of receptor agonism for a specific individual
Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, Lyssenko V, Bouatia-Naji N, Dupuis J, Jackson AU, et al
